FDA grants priority review for iberdomide-based myeloma regimen

1. The FDA has granted priority review for iberdomide, a first-in-class oral CELMoD designed to degrade transcription factors more effectively than earlier agents.

2. Priority review was supported by Phase III data demonstrating that iberdomide combinations significantly improve minimal residual disease negativity in relapsed myeloma.

The FDA has officially accepted Bristol Myers Squibb’s application for iberdomide, granting it priority review status for the treatment of relapsed or refractory multiple myeloma. Iberdomide is the lead candidate for a new class of oral drugs called CELMoDs, which are essentially souped-up versions of the immunomodulatory agents clinicians have used for decades. The filing is anchored by the EXCALIBER-RRMM trial, which demonstrated that adding iberdomide to a daratumumab and dexamethasone backbone significantly improved minimal residual disease (MRD) negativity. This is a high-stakes moment for the agency, as it leans into using MRD as a surrogate endpoint to speed up approvals for blood cancers. For hematologists, this oral regimen offers a potentially more potent and manageable option for patients who have already cycled through standard therapies. The FDA has set a target action date of August 17, 2026, which could make it the first CELMoD on the market. By degrading specific transcription factors like Ikaros and Aiolos more effectively, iberdomide may overcome the resistance that often develops in late-stage disease. The drug’s oral availability provides a major benefit for patients seeking to avoid frequent clinic-based infusions. However, the market competition with newer CAR-T therapies and bispecific antibodies will be a factor in how it is utilized across lines of therapy. We are still waiting for mature progression-free survival data to see if the high MRD negativity rates translate into long-term remissions. The manageable safety profile seen so far suggests it could become a versatile partner in several novel combination strategies for refractory populations.

Image: PD

©2026 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.